Cerebral vasculitis;Zerebrale vaskulitis

Fortschritte der Neurologie Psychiatrie

Volumn 70, Issue 12, 2002, Pages 663-677

  Berlit, Peter ^a   Steinbrecher, A ^b  

^a ALFRIED KRUPP KRANKENHAUS   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE;

ANGIOGRAPHY; ARTICLE; BEHCET DISEASE; BIOPSY; BLOOD ANALYSIS; BRAIN DISEASE; BRAIN VASCULITIS; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; HEADACHE; IMMUNOSUPPRESSIVE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; SYMPTOM; SYSTEMIC VASCULITIS; TREATMENT INDICATION; VASCULAR DISEASE;

ALKYLATING AGENTS; ANTI-INFLAMMATORY AGENTS; CEREBRAL ARTERIES; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; HUMANS; STEROIDS; VASCULITIS, CENTRAL NERVOUS SYSTEM;

EID: 0036910583     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-35855     Document Type: Article

References (101)

1. Padovan CS, Bise K, Hahn J et al. Angiitis of the central nervous system after allogeneic bone marrow transplantation? Stroke 1999; 30: 1651-1656
2. Schmidley JW. Central Nervous System Angiitis. Boston: Butterworth-Heinemann, 2000
3. Biller J, Loftus CM, Moore SA, Schelper RL, Danks KR, Cornell SH. Isolated central nervous system angiitis first presenting as spontaneous intracranial hemorrhage. Neurosurgery 1987; 20: 310-315
4. Calabrese LH, Mallek JA. Primary angiitis of the central nervous system. Report of 8 new cases, review of the literature, and proposal for diagnostic criteria. Medicine (Baltimore) 1988; 67: 20-39
5. Hankey GJ. Isolated angiitis/angiopathy of the central nervous system. Cerebrovasc Dis 1991; 1: 2-15
6. Younger DS, Hays AP, Brust JC, Rowland LP. Granulomatous angiitis of the brain. An inflammatory reaction of diverse etiology. Arch Neurol 1988; 45: 514-1518
7. Calabrese LH, Furlan AJ, Gragg LA, Ropos TJ. Primary angiitis of the central nervous system: Diagnostic criteria and clinical approach. Cleve Clin J Med 1992; 59: 293-306
8. Vollmer TL, Guarnaccia J, Harrington W, Pacia SV, Petroff OA. Idiopathic granulomatous angiitis of the central nervous system. Diagnostic challenges. Arch Neurol 1993; 50: 925-930
9. Stone JH, Pomper MG, Roubenoff R, Miller TJ, Hellmann DB. Sensitivities of noninvasive tests for central nervous system vasculitis: A comparison of lumbar puncture, computed tomography, and magnetic resonance imaging. J Rheumatol 1994; 21: 1277-1282
10. Pomper MG, Miller TJ, Stone JH, Tidmore WC, Hellmann DB. CNS vasculitis in autoimmune disease: MR imaging findings and correlation with angiography. Am J Neuroradiol 1999; 20: 75-85
11. Alrawi A, Trobe JD, Blaivas M, Musch DC. Brain biopsy in primary angiitis of the central nervous system. Neurology 1999; 53: 858-860
12. Chu CT, Gray L, Goldstein LB, Hulette CM. Diagnosis of intracranial vasculitis: A multi-disciplinary approach. J Neuropathol Exp Neurol 1998; 57: 30-38
13. Duna GF, Calabrese LH. Limitations of invasive modalities in the diagnosis of primary angiitis of the central nervous system. J Rheumatol 1995; 22: 662-667
14. Parisi JE, Moore PM. The role of biopsy in vasculitis of the central nervous system. Semin Neurol 1994; 14: 341-348
15. Moore PM. Diagnosis and management of isolated angiitis of the central nervous system. Neurology 1989; 39: 167-173
16. Berlit P. The spectrum of vasculopathies in the differential diagnosis of vasculitis. Sem Neurol 1994; 14: 370-379
17. Calabrese LH, Gragg LA, Furlan AJ. Benign angiopathy. A distinct subset of angiographically defined primary angiitis of the CNS. J Rheumatol 1993; 20: 2046-2050
18. Woolfenden AR, Tong DC, Marks MP et al. Angiographically defined primary angiitis of the CNS: Is it really benign? Neurology 1998; 51: 183-188
19. Berlit P. Vaskulitis. In: Hamann-Siebler-von Scheidt (eds) Schlaganfall. Landsberg: Ecomed, 2002
20. Caselli RJ, Hunder GG. Giant cell (temporal) arteritis. Neurol Clin 1997; 15: 893-902
21. Levine SM, Hellmann DB. Giant cell arteritis. Curr Opin Rheumatol 2002; 14: 3-10
22. Berlit P. Giant Cell Arteritis. In: Lechtenberg R, Schutta HS (eds). Practice Guidelines for Neurologic Therapy. New York: Marcel Dekker, 1997
23. Schmidt WA, Kraft HE, Vorpahl K, Völker L, Gromnica-Ihle EJ. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 1997; 337: 1336-1342
24. De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: A double-blind study. Ann Rheum Dis 1986; 45: 136-138
25. Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 2001; 19: 495-501
26. Liozon F, Vidal E, Gaches F, Venot J, Liozon E, Cransac M, Loustaud V, Berdah JF. Death in Horton disease. Prognostic factors. Rev Med Interne 1992; 13: 187-191
27. Caselli RJ, Hunder GG. Neurologic aspects of giant cell (temporal) arteritis. Rheum Dis Clin North-Am 1993; 19: 941-953
28. Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994; 37: 578-582
29. Shelhamer JH, Volkman DJ, Parrillo JE, Lawley TJ, Johnston MR, Fauci AS. Takayasu's arteritis and its therapy. Ann Intern Med 1985; 103: 121-126
30. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffmann GS, Hunder GG, Kallenberg CG et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-192
31. Watts RA, Jolliffe VA, Carruthers DM, Lockwood M, Scott DG. Effect of classification on the incidence of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum 1996; 39: 1208-1212
32. Vassilopoulos D, Calabrese LH. Hepatitis C virus infection and vasculitis: Implications of antiviral and immunosuppressive therapies. Arthritis Rheum 2002; 46: 585-597
33. Langford CA. Treatment of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: Where do we stand? Arthritis Rheum 2001; 44: 508-512
34. Gayraud M, Guillevin L, Toumelin Ple, Cohen P, Lhote F, Casassus P et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: Analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44: 666-675
35. Gayraud M, Guillevin L, Cohen P, Lhote F, Cacoub P, Deblois P et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: Comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol 1997; 36: 1290-1297
36. Haubitz M, Schellong S, Gobel U, Schurek HJ, Schaumann D, Koch KM et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: A prospective, randomized study. Arthritis Rheum 1998; 41: 1835-1844
37. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD et al. Wegener granulomatosis: An analysis of 158 patients. Ann Intern Med 1992; 116: 488-498
38. Reinhold-Keller E, Kekow J, Schnabel A, Schmitt WH, Heller M, Beigel A et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum 1994; 37: 919-924
39. Guillevin L, Lhote F, Leon A, Fauvelle F, Vivitski L, Trepo C. Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients. J Rheumatol 1993; 20: 289-298
40. Guillevin L, Lhote F, Cohen P, Sauvaget F, Jarrousse B, Lortholary O et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine 1995; 74: 238-253
41. Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, Thibult N, Casassus P. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine 1996; 75: 17-28
42. Lamprecht P, Gause A. Poly(Pan-)arteriitis nodosa, M. Kawasaki. In: Gross WL, ed. Therapie der Immunvaskulitiden. Bremen: UNI-MED, 2000: 70-80
43. Groot Kde, Schmidt DK, Arlt AC, Gross WL, Reinhold-Keller E. Standardized neurologic evaluations of 128 patients with Wegener granulomatosis. Arch Neurol 2001; 58: 1215-1221
44. Nishino H, Rubino FA, DeRemee RA, Swanson JW, Parisi JE. Neurological involvement in Wegener's granulomatosis An analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol 1993; 33: 4-9
45. Metzler C, Reinhold-Keller E. Wegenersche granulomatose. In: Gross WL, editor. Therapie der Immunvaskulitiden. Bremen: UNI-MED, 2000: 82-93
46. Bajema IM, Hagen EC. Evolving concepts about the role of antineutrophil cytoplasm autoantibodies in systemic vasculitides. Curr Opin Rheumatol 1999; 11: 34-40
47. Hagen EC, Daha MR, Hermans J, Andrassy K, Csernok E, Gaskin G et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998; 53: 743-753
48. Jennette JC, Wilkman AS, Falk RJ. Diagnostic predictive value of ANCA serology. Kidney Int 1998; 53: 796-798
49. McRae D, Buchanan G. Long-term sulfamethoxazole-trimethoprim in Wegener's granulomatosis. Arch Otolaryngol Head Neck Surg 1993; 119: 103-105
50. Valeriano-Marcet J, Spiera H. Treatment of Wegener's granulomatosis with sulfamethoxazole-trimethoprim. Arch Intern Med 1991; 151: 1649-1652
51. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40: 2187-2198
52. Steppat D, Gross WL. Stage-adapted treatment of Wegener's granulomatosis. First results of a prospective study. Klin Wochenschr 1989; 67: 666-671
53. Groot Kde, Muhler M, Reinhold-Keller E, Paulsen J, Gross WL. Induction of remission in Wegener's granulomatosis with low dose methotrexate. J Rheumatol 1998; 25: 492-495
54. Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis: Induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999; 42: 2666-2673
55. Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38: 608-613
56. Stone JH, Tun W, Hellman DB. Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J Rheumatol 1999; 26: 1134-1139
57. De Groot K, Reinhold-Keller E, Tatsis E, Paulsen J, Heller M, Nolle B et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 1996; 39: 2052-2061
58. Reinhold-Keller E, De Groot K, Rudert H, Nolle B, Heller M, Gross WL. Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. QJM 1996; 89: 15-23
59. Stegeman CA, Cohen Tervaert JW, Jong PEde, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996; 335: 16-20
60. Jayne DR, Chapel H, Adu D, Misbah S, O'Donoghue D, Scott D et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000; 93: 433-439
61. Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996; 124: 477-484
62. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76-85
63. Girard T, Mahr A, Noel LH, Cordier JF, Lesavre P, Andre MH et al. Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. Rheumatology (Oxford) 2001; 40: 147-151
64. Chang Y, Kargas SA, Goates JJ, Horoupian DS. Intraventricular and subarachnoid hemorrhage resulting from necrotizing vasculitis of the choroid plexus in a patient with Churg-Strauss syndrome. Clin Neuropathol 1993; 12: 84-87
65. Berlit P. Neurologische manifestationen von kollagenosen und vaskulitiden. Akt Neurol 2000; 27: 405-411
66. Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: A clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984; 63: 65-81
67. Metzler C, Tatsis E. Churg-Strauss-syndrom. In: Gross WL, ed. Therapie der Immunvaskulitiden. Bremen: UNI-MED, 2000: 104-113
68. Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 1998; 129: 370-374
69. De Groot K, Reinhold-Keller E. Mikroskopische polyangiitis. In: Gross WL, ed. Therapie der Immunvaskulitiden. Bremen: UNI-MED, 2000: 136
70. Askari A, Saadeh A, Buheis NI. Microscopic polyangiitis presenting as schizophrenia. Rheumatol Int 1999; 18: 215-217
71. Kono H, Inokuma S, Nakayama H, Yamazaki J. Pachymeningitis in microscopic polyangiitis (MPA): A case report and a review of central nervous system involvement in MPA. Clin Exp Rheumatol 2000; 18: 397-400
72. Deshpande PV, Gilbert R, Alton H, Milford DV. Microscopic polyarteritis with renal and cerebral involvement. Pediatr Nephrol 2000; 15: 134-135
73. Ehrlich GE. Vasculitis in Behçet's disease. Int Rev Immunol 1997; 14: 81-88
74. Yazici H, Yurdakul S, Hamuryudan V. Behçet's disease. Curr Opin Rheumatol 2001; 13: 18-22
75. Kidd D, Steuer A, Denman AM, Rudge P. Neurological complications in Behçet's syndrome. Brain 1999; 122: 2183-2194
76. Akman-Demir G, Serdaroglu P, Tasci B. Clinical patterns of neurological involvement in Behçet's disease: Evaluation of 200 patients. The Neuro-Behçet Study Group. Brain 1999; 122: 2171-2182
77. Coban O, Bahar S, Akman-Demir G, Tasci B, Yurdakul S, Yazici H et al. Masked assessment of MRI findings: Is it possible to differentiate neuro-Behçet's disease from other central nervous system diseases? Neuroradiology 1999; 41: 255-260
78. Serdaroǧlu P. Behçet's disease and the nervous system. J Neurol 1998; 245: 197-205
79. Sharief MK, Hentges R, Thomas E. Significance of CSF immunoglobulins in monitoring neurologic disease activity in Behçet's disease. Neurology 1991; 41: 1398-1401
80. Siva A, Fresko II. Behçet's disease. Curr Treat Options Neurol 2000; 2: 435-448
81. Kaklamani VG, Kaklamanis PG. Treatment of Behçet's disease - An update. Semin Arthritis Rheum 2001; 30: 299-312
82. Demiroglu H, Ozcebe OI, Barista I, Dundar S, Eldem B. Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behçet's disease: A randomised trial. Lancet 2000; 355: 605-609
83. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med 1999; 341: 1284-1291
84. Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR. Systemic lupus erythematosus. Lancet 2001; 357: 1027-1032
85. Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: Positive feedback in systemic autoimmune disease. Nature Rev Immunol 2001; 1: 147-153
86. Sibbitt Jr WL, Sibbitt RR, Brooks WM. Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2026-2038
87. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus. Arthritis Rheum 1999; 42: 599-608
88. Morton SJ, Powell RJ. Management of systemic lupus erythematosus (SLE). Clin Exp Allergy 2001; 31: 686-693
89. Mosca M, Ruiz-Irastorza G, Khamashta MA, Hughes GR. Treatment of systemic lupus erythematosus. Int Immunopharmacol 2001; 1: 1065-1075
90. Quisimorio FP. Systemic corticosteroid therapy in systemic lupus erythematosus. In: Wallace DJ and Hahn BH, eds. Dubois' Lupus Erythematosus. Baltimore: Williams & Wilkins, 1997: 1141-1162
91. Ortmann RA, Klippel JH. Update on cyclophosphamide for systemic lupus erythematosus. Rheum Dis Clin North Am 2000; 26: 363-375, vii
92. Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996; 125: 549-557
93. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248-257
94. Takada K, Illei GG, Boumpas DT. Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 2001; 10: 154-161
95. D'Cruz D, Cuadrado MJ, Mujic F, Tungekar MF, Taub N, Lloyd M et al. Immunosuppressive therapy in lupus nephritis. Clin Exp Rheumatol 1997; 15: 275-282
96. Chan TM, Li FK, Hao WK, Chan KW, Lui SL, Tang S et al. Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus 1999; 8: 545-551
97. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-1162
98. Mok CC, Ho CT, Chan KW, Lau CS, Wong RW. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 2002; 46: 1003-1013
99. Ruiz-Irastorza G, Khamashta MA, Hughes GR. Antiaggregant and anticoagulant therapy in systemic lupus erythematosus and Hughes' syndrome. Lupus 2001; 10: 241-245
100. Moore P, Richardson B. Neurology of the vasculitides and connective tissue diseases. J Neurol Neurosurg Psychiat 1998; 65: 10-22
101. Alexander EL, Ranzenbach MR, Kumar AJ, Kozachuk WE, Rosenbaum AE, Patronas N, Harley JB, Reichlin M. Anti-Ro (SS-A) autoantibodies in central nervous system disease associated with Sjögren's syndrome (CNS-SS): Clinical, neuroimaging, and angiographic correlates. Neurology 1994; 44: 89-908